Ontology highlight
ABSTRACT:
SUBMITTER: Jimenez-Valerio G
PROVIDER: S-EPMC4870515 | biostudies-literature | 2016 May
REPOSITORIES: biostudies-literature
Cell reports 20160428 6
Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tumor cells distal and proximal to remaining vessels as a mechanism of resistance to antiangiogenic therapies in patient-derived RCC orthoxenograft (PDX) models and in clinical samples. This metabolic p ...[more]